Biotech investing can be a cruel mistress, as best-in-class treatment status and momentum behind a stock can suddenly evaporate. As if Dendreon
Is Dendreon doomed to be crushed under the monolithic weight of J&J or additional competitors lining up on the horizon? Or does the scrappy biotech still have an fighting chance? Watch the video and find out.
The Motley Fool owns shares of Johnson & Johnson, Exelixis, and Dendreon. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson and Exelixis; and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.